Mehmet Kemal Tur

Mehmet Kemal Tur

Auto-generated profile, based on publicly available information

Mehmet Kemal Tur

University Hospital, Justus-Liebig-University Giessen

Research Focus & Metrics

Academic Career Length

27Years (2000-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 November 2019 in Cancers
Verified
Journal Article
Open access
PDF file
AMAmaia Eleonora Maennling
Amaia Eleonora Maennling
MTMehmet Kemal Tur
Mehmet Kemal Tur
MNMarcus Niebert
Marcus Niebert
TKTorsten Klockenbring
Torsten Klockenbring
FZFelix Zeppernick
Felix Zeppernick
Ahmad Fawzi HussainAhmad Fawzi Hussain
Ahmad Fawzi Hussain
The epidermal growth factor receptor (EGFR) family contains four transmembrane tyrosine kinases (EGFR1/ErbB1, Her2/ErbB2, Her3/ErbB3 and Her4/ErbB4) and 13 secreted polypeptide ligands. EGFRs are overexpressed in many solid tumors, including breast, pancreas, head-and-neck, prostate, ovarian, renal, colon, and non-small-cell lung cancer. Such overexpression produces strong stimulation of downstream signaling pathways, which induce cell growth, cell differentiation, cell cycle progression, angiogenesis, cell motility and blocking of apoptosis.The high expression and/or functional activation of EGFRs correlates with the pathogenesis and progression of several cancers, which make them attractive targets for both diagnosis and therapy. Several approaches have been developed to target these receptors and/or the EGFR modulated effects in cancer cells. Most approaches include the development of anti-EGFRs antibodies and/or small-molecule EGFR inhibitors. This review presents the state-of-the-art and future prospects of targeting EGFRs to treat breast cancer.

1 November 2008 in Current Cancer Drug Targets
Verified
Journal Article
Closed access
PDF file
UWUlrich Wullner
Ulrich Wullner
INInga Neef
Inga Neef
AEAndreas Eller
Andreas Eller
MKMichael Kleines
Michael Kleines
MTMehmet Kemal Tur
Mehmet Kemal Tur
Stefan Dr. Stefan BarthStefan Dr. Stefan Barth
Stefan Dr. Stefan Barth
New strategies for cell type-specific delivery need to be developed if RNA interference is to realize its full therapeutic potential. One possible approach is the use of aptamers to deliver siRNAs selectively to tumor cells with appropriate antigens displayed on the surface. We used an aptamer that binds specifically to PSMA, a cell surface glycoprotein found in abundance on prostate cancer cells, and joined its 3 end to a siRNA specific for Eukaryotic Elongation Factor 2 mRNA (EEF2). This is an attractive target for cancer therapy because inhibiting EEF2 causes the rapid arrest of protein synthesis, inducing apoptosis and leading ultimately to cell death. In order to enhance the therapeutic efficacy of the aptamer-siRNA, we increased the valency of the construct by rational design. Two anti-PSMA aptamers were designed such that each binding sequence could fold independently into its active conformation. Here we show specific cytotoxicity resulting from siRNA-induced silencing of EEF2, as well as specific delivery to PSMA-expressing prostate cancer cells. Increasing the valency of the aptamer resulted in enhanced cytotoxicity compared with the monovalent constructs. The results presented here demonstrate the usefulness of multivalent aptamer-based delivery vehicles for siRNA therapeutics.

1 September 2008 in Molecular Cancer Therapeutics
Verified
Journal Article
Closed access
BSBettina Stahnke
Bettina Stahnke
TTTheo Thepen
Theo Thepen
MSMichael StöcKer
Michael StöcKer
RRReinhard Rosinke
Reinhard Rosinke
EJEdgar Jost
Edgar Jost
Stefan Dr. Stefan BarthStefan Dr. Stefan Barth
Stefan Dr. Stefan Barth
Acute myeloid leukemia (AML) cells of subtypes M4 and M5 show enhanced expression of CD64 (FcγRI), the high-affinity receptor for IgG, which is normally expressed at high levels only on activated cells of the myeloid lineage. CD64 is therefore a prime target for the specific delivery of cytotoxic agents. A promising toxin candidate is granzyme B, a human serine protease originating from cytotoxic granules of CD8+ T lymphocytes and natural killer cells. After evaluating the sensitivity of the AML-related cell line U937 toward cytosolic granzyme B, we genetically fused granzyme B to H22, a humanized single-chain antibody fragment (scFv) specific for CD64, to obtain Gb-H22(scFv), a fusion protein lacking the immunogenic properties of nonhuman immunofusions. Gb-H22(scFv) was successfully expressed in human 293T cells, secreted, and purified from cell culture supernatants. The purified protein bound specifically to CD64+ U937 cells. Despite linkage to the binding domain, the proteolytic activity of functional Gb-H22(scFv) was identical to that of free granzyme B. Target cell-specific cytotoxicity was observed with a half-maximal inhibitory concentration (IC50) between 1.7 and 17 nmol/L. In addition, the induction of apoptosis in U937 cells was confirmed by Annexin A5 staining and the detection of activated caspase-3 in the cytosol. Finally, apoptosis was observed in primary CD64+ AML cells, whereas CD64− AML cells were unaffected. This is the first report of a completely human granzyme B-based immunotoxin directed against CD64, with activity against an AML-related cell line and primary AML cells. [Mol Cancer Ther 2008;7(9):2924–32]

13 October 2011 in Bioconjugate Chemistry
Verified
Journal Article
Closed access
AHAhmad Fawzi Hussain
Ahmad Fawzi Hussain
FKFlorian Kampmeier
Florian Kampmeier
VFVerena von Felbert
Verena von Felbert
HMHans-F. Merk
Hans-F. Merk
MTMehmet Kemal Tur
Mehmet Kemal Tur
Stefan Dr. Stefan BarthStefan Dr. Stefan Barth
Stefan Dr. Stefan Barth

1 April 2003 in Protein Expression and Purification
Verified
Journal Article
Closed access
MSMichael Stöcker
Michael Stöcker
MTMehmet K. Tur
Mehmet K. Tur
SSStephanie Sasse
Stephanie Sasse
AKAnne Krüßmann
Anne Krüßmann
Stefan Dr. Stefan BarthStefan Dr. Stefan Barth
Stefan Dr. Stefan Barth
AEAndreas Engert
Andreas Engert

17 September 2013 in BioDrugs
Verified
Journal Article
Closed access
PDF file
TSThomas Schirrmann
Thomas Schirrmann
MSMiriam Steinwand
Miriam Steinwand
XWXenia Wezler
Xenia Wezler
AHAndre Ten Haaf
Andre Ten Haaf
MTMehmet K. Tur
Mehmet K. Tur
Stefan Dr. Stefan BarthStefan Dr. Stefan Barth
Stefan Dr. Stefan Barth